Concordia Healthcare Corp. T.CXR.R

Analyst Review

[BaytexBull]

SELL	Christine Poole	Has never owned this. This company grows by acquisition. They’ve had some problems in the past quarter when they cut their guidance going forward, and had to write down the value of some of their drugs. They also have a big debt load. There is poor visibility on their earnings. The CFO is leaving and there is an interim CFO stepping in. There is a lot of confusion as to what the company is going to look like going forward. If you own, she would recommend you cut your loss.     / Be the first to comment	Price: $11.940 Subject: NORTH AMERICAN - LARGE Bias: OPTIMISTIC Owned: No